Amneal Pharmaceuticals, Inc. filings document the regulatory record for a pharmaceutical issuer with Affordable Medicines, Specialty and AvKARE operations. The company’s 8-K reports cover operating and financial results, Regulation FD communications, clinical or regulatory disclosures, material agreements and capital-structure matters, including amendments to term loan credit arrangements involving Amneal Pharmaceuticals LLC and subsidiary guarantors.
Amneal’s proxy and annual-meeting filings describe board elections, advisory executive-compensation votes, auditor ratification and other stockholder voting matters. Its material-event disclosures also record governance matters, shareholder votes, opioids-related settlement obligations, and financial-statement exhibits tied to press releases and other public-company reporting.
Amneal Pharmaceuticals reported strong first quarter 2026 results. Net revenue was $722.5 million, up 4% from $695.4 million a year earlier, driven by 23% Specialty growth and 2% Affordable Medicines growth, partly offset by a 4% AvKARE decline.
Net income attributable to Amneal rose to $62.3 million from $12.2 million, while adjusted EBITDA increased 19% to $202.0 million. Diluted EPS was $0.19 versus $0.04, and adjusted diluted EPS was $0.27 versus $0.21, reflecting higher revenue and improved gross margins.
The company affirmed its increased 2026 outlook, guiding to net revenue of $3.05–$3.15 billion, adjusted EBITDA of $740–$770 million, adjusted diluted EPS of $0.95–$1.05, operating cash flow of $350–$400 million, and about $110 million in capital expenditures.
BlackRock, Inc. reports beneficial ownership of 7.6% of Amneal Pharmaceuticals, Inc. common stock, holding 24,121,119 shares as of 03/31/2026. The filing states these shares are attributed to certain "Reporting Business Units" of BlackRock, in accordance with SEC Release No. 34-39538 (January 12, 1998).
Amneal Pharmaceuticals agreed to acquire 100% of Kashiv BioSciences, paying $375 million in cash and issuing 28,942,108 Class A shares at closing, plus up to $350 million in regulatory milestone payments and potential royalties based on future gross profits.
The deal, expected to close in the second half of 2026 subject to shareholder and regulatory approvals, is intended to create a scaled, fully integrated global biosimilars platform. An independent conflicts committee approved the transaction terms and will recommend that stockholders approve the stock issuance and Purchase Agreement.
Alongside the deal, Amneal reported strong preliminary Q1 2026 results, with net revenue of $723 million, net income of $78 million and adjusted EBITDA of $202 million, and raised 2026 guidance for adjusted EBITDA, adjusted diluted EPS and operating cash flow.
Patel Chintu reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals reported that Co-CEO Chintu Patel received a grant of 544,663 performance-based restricted stock units, each tied to one share of Class A common stock. The award vests based on the stock achieving specified average closing price targets over a three-year performance period.
The number of shares ultimately earned can range from 0% to 200% of the target amount, depending on performance. Any earned units are scheduled to vest in full on February 28, 2029. This is a compensation grant at no cash cost per unit, not an open-market purchase or sale.
Amneal Pharmaceuticals President & Co-CEO Chirag K. Patel received a grant of 544,663 performance-based restricted stock units tied to Class A common stock. These units do not involve a cash purchase and represent a compensation award that can convert into shares in the future.
The award is based on Amneal’s Class A common stock achieving specified average closing price targets over a three-year performance period. The number of shares ultimately earned can range from 0% to 200% of the 544,663 target, with the table reflecting the maximum shares potentially issuable. Any units that are earned will vest in full on February 28, 2029, at the end of the performance period.
Dipan Patel filed Amendment No. 5 to a Schedule 13D for Amneal Pharmaceuticals, Inc., updating his beneficial ownership in the company’s Class A common stock. The filing reports beneficial ownership of 16,904,263 shares, representing 5.4% of the Class A common stock, based on 314,629,101 shares outstanding disclosed in Amneal’s Form 10-K filed on February 27, 2026.
Between November 14, 2024 and December 31, 2025, trusts controlled by Patel sold 6,924,729 Amneal Class A shares in open market transactions at prices between $7.74 and $12.42 per share. After these sales, Patel, through those trusts, retains sole voting and dispositive power over the 16.9 million shares reported.
The Vanguard Group amended its Schedule 13G/A to report zero beneficial ownership of Amneal Pharmaceuticals Inc. common stock. The filing states Vanguard holds 0 shares (0%) and discloses an internal realignment effective January 12, 2026 that led to disaggregated reporting by subsidiaries.
Amneal Pharmaceuticals uses this proxy to review 2025 performance, outline governance, and seek support for electing 10 directors and approving executive pay. The company reports its sixth straight year of growth, with 2025 net revenue of $3,019 million, up from $2,794 million, and Adjusted EBITDA up 10%. Net income improved to $72 million with diluted EPS of $0.22, compared with a $117 million loss and diluted EPS of $(0.38) in 2024. Management highlights strong contributions from Affordable Medicines, double-digit growth in Specialty and AvKARE, multiple new product approvals, and an expanded biosimilars and GLP‑1 pipeline. Net leverage fell to 3.5x, versus 7.4x in 2019, after refinancing debt to extend maturities to 2032. The filing also describes Amneal’s transition away from controlled-company status, current board composition and committees, director compensation and ownership guidelines, and a pay‑for‑performance program tying a significant portion of executive compensation to annual and long‑term results.
Amneal Pharmaceuticals, Inc. director and Co-CEO Chintu Patel reported vesting and settlement of several equity awards into Class A Common Stock. On March 3, 2026, performance-based restricted stock units granted on March 3, 2023 were certified at 200% of the targeted number, deemed earned and vested, and settled into shares on a one-for-one basis. Time-based restricted stock units also vested and were settled into Class A shares.
The gross shares issued from these vestings were partly withheld to cover tax withholding obligations, with multiple Form 4 code “F” transactions showing Class A shares withheld at $13.31 and $13.30 per share for taxes. After these transactions, Patel directly holds 1,388,521 shares of Class A Common Stock and 185,185 restricted stock units, and indirectly holds 24,753,252 Class A shares through family trusts.
Amneal Pharmaceuticals, Inc. President & Co-CEO Chirag K. Patel reported multiple equity award vestings and related share movements. On March 3, 2026, performance-based restricted stock units covering 733,944 units vested after achieving a performance threshold that resulted in vesting of 200% of the targeted number, and were settled into the same number of Class A Common shares on a one-for-one basis. Additional restricted stock units covering 59,931 units also converted into Class A Common Stock.
To cover tax withholding obligations from these vestings, the reporting person disposed of 297,537 and 15,616 Class A shares at per-share prices of $13.31, and on March 4, 2026 disposed of a further 37,825 Class A shares at $13.30, all characterized as share withholding rather than open-market sales. After these transactions, direct holdings reported include 1,393,470 shares of Class A Common Stock and 185,185 restricted stock units, with an additional 21,269,420 Class A shares held indirectly through family trusts.